Chinese Medicines and Natural Medicine as Immunotherapeutic Agents for Gastric Cancer: Recent Advances
- PMID: 39233637
- PMCID: PMC11375283
- DOI: 10.1002/cnr2.2134
Chinese Medicines and Natural Medicine as Immunotherapeutic Agents for Gastric Cancer: Recent Advances
Abstract
Backgroud: According to the 2020 statistics from the World Health Organization's International Agency for Research on Cancer (IARC), it is projected that there will be over 1 million new cases of gastric cancer (GC) patients worldwide in 2020, resulting in approximately 770 000 deaths. Gastric cancer ranks fifth in terms of incidence rate and forth in death rate among malignant tumors. Despite advancements in early diagnostic techniques, the incidence of GC has exhibited a marginal decline; nevertheless, the mortality rate remains elevated for advanced inoperable patients with no currently available efficacious treatment options.
Recent finding: Chinese medicine (CM) has emerged as an efficacious treatment for GC, gradually gaining acceptance and widespread usage in China. It exhibits distinctive advantages in the prevention and treatment of metastasis. CM and natural medicine possess the ability to elicit antitumor effects by augmenting immune cell population, enhancing immune cell activity, and improving the tumor immune microenvironment. CMs and natural remedies encompass a diverse range of types, characterized by multiple targets, pathways, and extensive pharmacological effects. Consequently, they have become a prominent research area among oncologists worldwide. Numerous studies have demonstrated that CM and natural medicine can directly or indirectly enhance innate immune system components (including macrophages, natural killer cells, and myeloid suppressor cells), adaptive immune system elements (such as T lymphocytes and regulatory T cells), relevant cytokines (e.g., IL-2, IL-4, IL-10, TNF-α), and PD-1/PD-L1 axis regulation, thereby bolstering the cytotoxicity of immune cells against tumor cells.
Conclusions: This ultimately leads to an improved tumor immune microenvironment facilitating superior antitumor efficacy. This paper critically examines the role of CM and natural medicine in regulating immunotherapy for GC, aiming to establish a new theoretical framework for the clinical treatment and prevention of gastric cancer within the realm of CM.
Keywords: Chinese medicine; gastric cancer; immunotherapy; research progress.
© 2024 The Author(s). Cancer Reports published by Wiley Periodicals LLC.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Reshaping the immune microenvironment and reversing immunosenescence by natural products: Prospects for immunotherapy in gastric cancer.Semin Cancer Biol. 2025 May;110:1-16. doi: 10.1016/j.semcancer.2025.02.002. Epub 2025 Feb 7. Semin Cancer Biol. 2025. PMID: 39923925 Review.
-
Antitumor effects of immunity-enhancing traditional Chinese medicine.Biomed Pharmacother. 2020 Jan;121:109570. doi: 10.1016/j.biopha.2019.109570. Epub 2019 Nov 9. Biomed Pharmacother. 2020. PMID: 31710893 Review.
-
Research Status and Molecular Mechanism of the Traditional Chinese Medicine and Antitumor Therapy Combined Strategy Based on Tumor Microenvironment.Front Immunol. 2021 Jan 21;11:609705. doi: 10.3389/fimmu.2020.609705. eCollection 2020. Front Immunol. 2021. PMID: 33552068 Free PMC article. Review.
-
Mechanisms of traditional Chinese medicine in the treatment and prevention of gastric cancer.Phytomedicine. 2024 Dec;135:156003. doi: 10.1016/j.phymed.2024.156003. Epub 2024 Sep 8. Phytomedicine. 2024. PMID: 39305742 Review.
-
The Role of Traditional Chinese Medicine in Cancer Immunotherapy: Current Status and Future Directions.Am J Chin Med. 2023;51(7):1627-1651. doi: 10.1142/S0192415X2350074X. Epub 2023 Aug 28. Am J Chin Med. 2023. PMID: 37638827
Cited by
-
Polydatin inhibits the stemness and angiogenesis of gastric cancer cells by targeting down-regulation of HDAC7.Discov Oncol. 2025 May 14;16(1):761. doi: 10.1007/s12672-025-02481-8. Discov Oncol. 2025. PMID: 40366512 Free PMC article.
References
-
- Sung H., Ferlay J., Siegel R. L., et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71 (2021): 209–249. - PubMed
-
- al‐Batran S. E., Homann N., Pauligk C., et al., “Perioperative Chemotherapy With Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel Versus Fluorouracil or Capecitabine Plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro‐Oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial,” Lancet 393 (2019): 1948–1957. - PubMed
-
- Fuchs C. S., Shitara K., di Bartolomeo M., et al., “Ramucirumab With Cisplatin and Fluoropyrimidine as First‐Line Therapy in Patients With Metastatic Gastric or Junctional Adenocarcinoma (RAINFALL): A Double‐Blind, Randomised, Placebo‐Controlled, Phase 3 Trial,” Lancet Oncology 20 (2019): 420–435. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 2022LJ014/Shanghai Municipal Health Leading Talents Program
- WLJH2021ZY-MZY020/Traditional Chinese Medicine Inheritance and Development Project of Shanghai Medical Innovation & Development Foundation
- 2021KJ03-12/Shanghai Frontier Research Base of Disease and Syndrome Biology of Inflammatory Cancer Transformation
- ZY(2021)-0211/Shanghai Traditional Chinese Medicine "Three-year Action Plan"
- 22Y11921300/Science and Technology Commission of Shanghai Municipality
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous